patients with poor prognosis. Gefitinib was an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor which has been used in the treatment of NSCLC. Our study was to evaluate the efficacy and toxicities of gefitinib in lung adenocarcinoma patients with brain metastases. Methods We retrospectively reviewed clinical records of 32 lung adenocarcinoma patients with brain metastases, who had received gefitinib 250 mg Qd until disease progression or intolerable toxicities. Results The median overall survival (mOS) and median progression-free survival (mPFS) were 24.7 months and 11.2 months, respectively.
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